Skip to content

Immunovant, Inc.

IMVT· Nasdaqxbrl foundCIK 1764013

Biological products, except diagnostic substances175 peers

Last sale
Nov 12, 2026 · -5.35%
Market cap
$7.25B
206.95M shares
Filings
653
—
—
—
-$97.25M
Q2 2027N/M FY26 yoy
-$419.76K
Q3 2019
—
-$407.32M
FY 2026derivedN/M FY26 yoy
-$0.47
Q2 2027N/M FY26 yoy
$722.27M
Q2 2027+26.4% FY26 yoy
$7.25B
—
—
11.0×
-5.62%
—

FY2026 figures · derived

Price

$35.04+53.01%+$12.14past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Net Interest Income

$24.95MFY 2024
$24.95M0FY 2022FY 2023FY 2024
PeriodEndedValueKindSource trail
FY 20242024-03-31$24,948,000reported
FY 20232023-03-31$7,578,000reported
FY 20222022-03-31$0reported

Biological products, except diagnostic substances

Immunovant, Inc. is the 17th largest of the 176 covered companies the SEC files under this code, by market cap. SIC 2836

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Immunovant, Inc. · CIK 1764013 · Engraved from SEC EDGAR